## 4.0.3 DOC Cmte minutes

## Abdominal Aortic Aneurysm Guideline Committee – development

**Date:** 15/12/2015

Location: NICE Offices, Manchester

Minutes:

Final



Committee members present:		
Andrew Bradbury (Chair)	Present for all	
Chris Hammond (CH)	Present for all	
Karen Jellett (KJ)	Present for all	
Jacqualine Lindridge (JL)	Present for all	
Adam Pichel (AP)	Present for all	
Tamsin Ribbons (TR)	Present for all	
Eshan Senanayake (ES)	Present for all	
Matthew Slater (MS)	Present for all	
Alan Huw Smith (AHS)	Present for all	
Sammer Tang (ST)	Present for all	
Matt Thompson (MT)	Present for all	
Noel Wilson (NW)	Present for all	

In attendance:		
Sue Ellerby (SE)	ICG – Clinical Advisor	Present for all
Sarah Glover (SG)	NICE – Information Specialist	Present for all
Lucy Hoppe (LH)	ICG – Technical Analyst	Present for all
Rachel Houten (RH)	ICG – Health Economist	Present for all
Sarah Mills (SM)	ICG – Project Manager	Present for all
Gabriel Rogers (GR)	ICG – Technical Advisor (HE)	Present for items 3 – 7
Sue Spiers (SSp)	ICG – Associate Director	Present for all
Lisa Stone (LS)	MPC – Medicines Advisor	Present for items 1 – 5

# 4.0.3 DOC Cmte minutes

Observers:	
Alison Lloyd	Technical Analyst

Apologies:		
Sarah Stephenson	NICE - Commissioning Manager	
Jugdeep Dhesi	Committee member	
Claire Martin	Committee member	
Gillian Kitching	Committee member	
Hugh McGuire	Technical Advisor	

## 1. Welcome, apologies, declarations of interest

The Chair welcomed the Committee members and attendees to the second meeting of the abdominal aortic aneurysm guideline committee.

Apologies for the meeting were received as detailed above.

It was noted that Roger Good a lay member on the committee had resigned due to personal reasons. The Chair welcomed Alan Huw Smith as a second lay member and informed the committee that an advert had been issued for another lay member. Also Sammer Tang and Jaqualine Lindridge were welcomed as two new paramedic co-opted members.

The Chair outlined the proposed main objectives of the meeting, which included:

- Agreeing review questions
- Signing off two review protocols

Minutes of the last meeting were agreed without any amendments.

It was noted that complex EVAR would be included in the scope of the guideline.

It was noted that the committee had received confirmation that the guideline will update *TA167 Endovascular-stent grafts in the treatment of abdominal aortic aneurysm.* 

The Declarations of Interest (DOI) register was made available to the Chair.

New declarations of interest defined as requiring consideration, for this or future meetings, by the NICE Conflict of Interest policy are outlined below:

Initials	Declaration	Classification	Chairs action
MT	Member of an Endologix advisory board and consultancy for company.	Specific, personal, financial	Declare and participate (to be excluded from future meetings where evidence on products made by this company is considered)
MT	Consultancy for Medtronic	Specific, personal, financial	Declare and participate (to be excluded from future meetings where evidence on products

			made by this company is considered)
MT	Principal Investigator of EVAS FORWARD Global Registry	Specific, personal, non-financial	Declare and participate (to be excluded from future meetings where evidence on products made by this company is considered)
MT	Speaker fees for Medtronic & Endologix	Specific, personal, financial	Declare and participate (to be excluded from future meetings where evidence on products made by these companies are considered)
AHS	Member of the National Abdominal Aortic Aneurysm Screening Programme research committee	Specific, personal, non-financial	Declare and participate. Does not need to be excluded from any future meetings.

The Chair reviewed the committee's DOI register and declared that in relation to previous declarations recorded in the DOI register and those declarations noted above, that no committee members would be required to withdraw from part or all of the meeting.

## 2. Proposed approach to obtaining and considering unpublished data

SS talked the committee through a paper outlining NICE's approach to obtaining and considering unpublished data.

It was noted that NICE's preferred and usual approach (as outlined in the Guideline's Manual) is to consider published, peer-reviewed evidence and that only evidence graded as high quality (using GRADE) could be utilised to support strong recommendations by the committee. The committee were made aware that it would be possible to issue a call for evidence or invite expert witnesses to the committee if it was believed that there was specific and relevant unpublished data that would be beneficial in the committee's deliberations. It was noted that where published evidence existed the value of seeking unpublished evidence should be considered carefully.

The committee discussed relevant possible sources of unpublished data. The committee were reminded that they would need to identify which review questions such data could be used for and the required format of such data to enable appropriate consideration of the evidence in relation to the review question.

# 4.0.3 DOC Cmte minutes

Action: it was agreed that the committee would seek to representatives from the following organisations as expert witnesses:

- National AAA Screening Programme
- National Vascular Registry

**Action:** committee to consider as review protocols are signed off which review questions may need the inclusion of further sources of unpublished data.

## 3. & 4. Review questions

LH presented the remaining draft review questions for amendment and agreement with the committee.

Committee members then volunteered to be a point of contact for technical queries from the technical analyst on specific questions.

It was noted that the term watchful waiting should be replaced with 'surveillance' and that the term 'prevent' should be used appropriately in the guideline.

Action: SM to circulate finalised review questions to the committee and ask for volunteers from absent committee members.

#### 5. Discuss and agree review protocols

The review protocols for the following questions were considered and agreed:

'Which non-surgical interventions (including drug treatment and risk factor management) are effective in preventing growth and rupture in people with unruptured abdominal aortic aneurysms?'

'What is the effectiveness of early referral for surgery and early surgery compared with a 'watchful waiting' approach in people with unruptured abdominal aortic aneurysms?'

Action: SM to circulate finalised review protocols for final comment.

## 6. Health economic priority setting

RH gave a presentation on health economic modelling. It was noted that the main focus of the modelling for this guideline would be the mandated update to TA167 [comparison of the effectiveness of EVAR compared to open repair surgery].

The committee also discussed other areas for potential health economic modelling, though it is unlikely these will be able to be completed due to limited resources.

## 7. AOB

The committee were reminded of the time and venue of the next committee meeting.

Date of next meeting:

Tuesday 26<sup>th</sup> January 2016

Location of next meeting:

NICE offices, Manchester